RheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.
In this video, Michelle Petri, MD, director of the Hopkins Lupus Center at Johns Hopkins University, discusses recent successes and challenges in the treatment of systemic lupus erythematosus, with clinical trials results ranging from "wildly positive" to "completely negative."
The risk of developing ankylosing spondylitis (AS) if you are HLA-B27+ and a first degree relative is often said to be 20%.
Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.
The International Osteoporosis Foundation (IOF) reports that nearly 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures.
The diagnosis of periodic fevers is unified by undiagnosed but recurrent fever. Unfortunately the diagnosis of these disorders is hampered by their infrequency, protean features and a lack of clear criteria. Even more problematic is knowing who should be tested and for which monogenic marker?
The October 7th edition of MMWR reports that severe joint pain (SJP) has significantly risen from 10.5 million in 2012 to 27.2% in 2014, based on recent NHIS surveys.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.